Merck’s cholesterol med anacetrapib delivered a surprise win in its cardiovascular outcomes trial. Did it win big enough to make a launch worthwhile?

GSK’s Nucala may soon get more competition in the severe asthma market. So the company is setting out to test Nucala in other populations, too.

Promius Pharma has a new PSA on migraines, building on its campaign to help migraine sufferers recognize many different types of migraine symptoms.

Chasing a $6 billion market opportunity, Bavarian Nordic reports that a dose of its universal RSV vaccine can elicit a significant immune response.

The New York judge presiding over the case against pharma entrepreneur and investor Martin Shkreli is struggling to find jurors who can be neutral.

New FDA Commissioner Scott Gottlieb has unveiled two new strategies aimed at tackling high drug costs right away.

A CDC advisory committee again recommended against using AstraZeneca's FluMist for the upcoming flu season.

Weeks after announcing a €5.32 billion ($5.63 billion) buyout, German generics maker Stada said the deal failed to get shareholder approval.